Zain Ul Abideen

Zain Ul Abideen

Auto-generated profile, based on publicly available information

Zain Ul Abideen

King Edward Medical University, Lahore, Pakistan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2025 in Brain and Behavior
Verified
Journal Article
Open access
MWMuhammad Hassan Waseem
Muhammad Hassan Waseem
ZAZain Ul Abideen
Zain Ul Abideen
MKMuhammad Haris Khan
Muhammad Haris Khan
MTMuhammad Fawad Tahir
Muhammad Fawad Tahir
MKMarium Khan
Marium Khan
JIJaved Iqbal
Javed Iqbal
Background: Tenecteplase (TNK) is a novel thrombolytic agent gaining attention as an alternative to alteplase for treating acute ischemic stroke (AIS). This meta‐analysis evaluates the safety and efficacy of various TNK doses compared to alteplase, integrating recent randomized controlled trials (RCTs) and employing a frequentist network meta‐analysis to identify the optimal dose while addressing existing evidence gaps.Methods: Up until December 2024, PubMed, Cochrane Central, and ScienceDirect were searched. Using Review Manager 5.4.1 for pairwise meta‐analysis, the Risk Ratios (RR) with 95% Confidence Intervals (CI) were pooled under the random effects model. Additionally, R version 4.3.2 and the “netmeta” package were used to conduct a network meta‐analysis for various dosages of the two thrombolytic drugs.Results: Thirteen RCTs, pooling 9,044 patients, were included in the quantitative synthesis. TNK was associated with a statistically significant improvement in the excellent functional outcome (mRS 0–1) (RR = 1.04; 95% CI: [1.00, 1.08]; p = 0.03) compared to alteplase. No significant differences were observed between TNK and alteplase in terms of good functional outcome (mRS 0–2), poor functional outcome (mRS 5–6), major neurological improvement within 72 h, symptomatic intracranial hemorrhage (sICH), or mortality at 90 days. On network analysis, TNK 0.25 mg/kg showed significant improvement in excellent functional outcome (RR = 1.05, 95% CI: [1.01, 1.10]) and TNK 0.32 mg/kg in good functional outcome (1.30, 95% CI: [1.15, 1.48]) compared to alteplase. According to the P‐score ranking, TNK 0.25 mg/kg was ranked as the best for achieving an excellent outcome (P‐score = 0.86), and TNK 0.1 mg/kg as the worst (P‐score = 0.16). For symptomatic intracranial hemorrhage (sICH), alteplase 0.9 mg/kg was ranked as the best (P‐score = 0.71), and TNK 0.4 mg/kg as the worst (P‐score = 0.17).Conclusion: TNK (0.25‐0.32 mg/kg) demonstrates superior efficacy compared to alteplase in achieving functional outcomes for AIS, while alteplase remains safer regarding sICH. Optimal dosing favors TNK 0.25 mg/kg for efficacy, but safety considerations highlight the need for individualized thrombolytic selection.

29 January 2025 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
PDF file
MWMuhammad Hassan Waseem
Muhammad Hassan Waseem
ZAZain Ul Abideen
Zain Ul Abideen
RDRafia Durrani
Rafia Durrani
EDEsha Dilawar
Esha Dilawar
MKMohammad Saboor Kamran
Mohammad Saboor Kamran
SQShurjeel Uddin Qazi
Shurjeel Uddin Qazi

25 August 2025 in The Neuroradiology Journal
Verified
Journal Article
Closed access
MWMuhammad Hassan Waseem
Muhammad Hassan Waseem
ZAZain Ul Abideen
Zain Ul Abideen
KFKanza Farhan
Kanza Farhan
HKHaseeb Javed Khan
Haseeb Javed Khan
DGDua Ghori
Dua Ghori
ZFZara Fahim
Zara Fahim
Acute basilar artery occlusion (BAO) can lead to severe stroke and is linked to significant disability or death if not treated. This meta-analysis evaluated the effectiveness and safety of first-line thrombectomy options: Direct Aspiration (DA) and Stent Retriever Thrombectomy (SRT) for acute BAO. Electronic databases, including PubMed, Cochrane Central, ScienceDirect, Embase, and Web of Science were searched from inception until July 2025. Studies were included if they were RCTs or observational cohorts involving adults with acute BAO, comparing DA and SRT. The risk ratios (RR) and mean differences (MD) were pooled using Review Manager version. The Newcastle–Ottawa Scale (NOS) was used to assess quality. This meta-analysis included fifteen observational studies pooling 2214 patients. DA significantly increased the postoperative successful (RR = 1.04; 95% CI: 1.01 to 1.07; p = 0.008) and complete (RR = 1.19; 95% CI: 1.03 to 1.38; p = 0.02) recanalization compared to SRT. Similarly, symptomatic intracerebral hemorrhage (sICH) incidence was significantly reduced in the DA arm (RR = 0.65; 95% CI: 0.44 to 0.97; p = 0.04). DA is also associated with decreased procedural duration (MD = −35.17 min; 95% CI: −47.97 to −22.37; p < 0.00001). Meanwhile other outcomes, including postoperative mortality, rescue therapy, and favorable functional outcome were comparable between the 2 groups. DA demonstrated superior recanalization rates, reduced procedural duration, and a lower incidence of sICH compared to SRT. However, both techniques were comparable regarding other outcomes. Nevertheless, the observational study design limits the strength of the conclusion drawn.

24 February 2025 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
MWMuhammad Hassan Waseem
Muhammad Hassan Waseem
ZAZain Ul Abideen
Zain Ul Abideen
AAAyesha Ahmed
Ayesha Ahmed
BSBarka Sajid
Barka Sajid
ACAmeer Haider Cheema
Ameer Haider Cheema
SASania Aimen
Sania Aimen


19 March 2025 in Blood Coagulation & Fibrinolysis
Verified
Journal Article
Closed access
MWMuhammad Hassan Waseem
Muhammad Hassan Waseem
ZAZain Ul Abideen
Zain Ul Abideen
NRNohela Rehman
Nohela Rehman
SASarosh Ali
Sarosh Ali
EDEsha Dilawar
Esha Dilawar
AMAreehah Zafar Masood
Areehah Zafar Masood
Venous thromboembolism (VTE) remains a significant cause of perioperative morbidity and mortality despite the availability of prophylactic medications. There has been a debate about which thromboprophylaxis medication, Fondaparinux or low-molecular weight heparin (LMWH), is better after hip and knee arthroplasty. We have compared these two treatment regimens in our study. Electronic databases like PubMed, Cochrane, and ScienceDirect were searched from inception to August 2024. The weighted mean difference (WMD) for continuous outcomes and risk ratio (RR) for dichotomous outcomes were pooled using the Review Manager software version 5.4.1, and a random effects model was employed. The Newcastle-Ottawa Scale and Cochrane Risk of Bias Tool (ROB 2.0) were used to assess the quality of the included studies. Publication bias was evaluated visually through funnel plots and statistically through Egger's regression. GRADE assessment was used to analyze the certainty of evidence. A total of 17 studies, 9 Cohorts, and 8 Randomized controlled trials (RCTs) pooling a total of 74 499 patients were included in this meta-analysis. Fondaparinux showed a statistically significant reduction in the risk of VTE [0.59; 95% confidence interval (CI): [0.48, 0.71]; P < 0.00001; I 2 = 36%] and deep venous thrombosis (DVT) (RR = 0.75, 95% CI: [0.56, 1.00]; P = 0.05; I 2 = 68%) compared to LMWH. Major bleeding (RR = 2.06, 95% CI: [1.19, 3.57]; P = 0.01; I 2 = 43%), surgical site bleeding (RR = 1.67, 95% CI: [1.04, 2.66]; P = 0.03; I 2 = 9%), and postoperative transfusions (RR = 1.07, 95% CI: [1.02, 1.12]; P = 0.004; I 2 = 0%) were significantly higher in the Fondaparinux group. Symptomatic VTE, pulmonary embolism, mortality, and operating time showed no significant difference between the two groups. In conclusion, Fondaparinux is superior to LMWH in VTE and DVT prophylaxis. However, it is associated with an increased risk of major bleeding, surgical site bleeding, and postoperative transfusions.